Investors
and Media

Investor Overview

Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

  • Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] was approved by the FDA on May 3, 2018. Learn more.
  • Bevyxxa® (betrixaban) was approved by the FDA on June 23, 2017. Learn more.
  • Cerdulatinib – Investigational, oral, dual-spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitior. Portola has worldwide rights to develop and commercialize cerdulatinib. Learn more.
Stock Info
NASDAQPTLA
Corporate Presentation
Recent News
May 18, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of...

May 14, 2020

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa®...

May 11, 2020

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to...

More ›

Annual Report